NCT03263936 2025-10-16
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
Therapeutic Advances in Childhood Leukemia Consortium
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Therapeutic Advances in Childhood Leukemia Consortium